Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have had stage III or IV melanoma fully removed by surgery and are being treated with an immunotherapy drug (such as pembrolizumab, nivolumab, or a similar type of drug called an immune checkpoint inhibitor) as a follow-up treatment after surgery
- People with advanced stage IIIC/D or IV melanoma that cannot be surgically removed, who are being treated with immunotherapy (such as pembrolizumab, nivolumab, or a similar immune checkpoint inhibitor) combined with radiotherapy
- People who have been informed about the study and have signed a consent form agreeing to take part
- People enrolled in the French social security system
Who may not be able to join:
- Women who are pregnant or breastfeeding
- People who do not wish to take part
- People currently taking immunosuppressant medication (drugs that lower the immune system's activity)
- People who have been taking high-dose steroid tablets (more than 10 mg/kg/day) for more than 7 days
- People currently participating in another clinical trial where they are receiving a blinded (unknown) treatment
- People who do not have any form of social security or health protection coverage
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elisa FUNCK-BRENTANO, MD, Dermato-oncology department, Ambroise Paré hospital, APHP
Phone: +33 (0)1 71 16 77 21
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of relapse/progression-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.